This site is intended only for healthcare professionals residing in Singapore




Sign InLog Out
Our medicinesTherapy areasExplore contentExplore contentEventsMaterialsVideosLet’s connectLet's ConnectContact usPfizer medical information
AMSResist the ResistanceAct now. Act how?Strategy to prevent catastropheSurveil. SurvivePolicy for PurposeBacterial InfectionsBacterial basicsDetection and selectionKnow the negativeThe HAP/VAP recapDispel the MBLPinpoint the positiveGo-to guidelinesFungal InfectionsFungal factsFind the fungiPolice the yeastBehold the mouldFight the fungiViral InfectionsVerdict on virusesResourcesViral Infections



Resist the ResistanceAct now. Act how?Strategy to prevent catastropheSurveil. SurvivePolicy for Purpose
Dispel the MBL

Antimicrobial resistance (AMR) is a growing threat, especially among Gram-negative bacteria. Emergence of resistance to β-lactam antibiotics - the most potent and prescribed class of antibiotic - is mainly due to the production of β-lactamase enzymes. Metallo-β-lactamase (MBL) enzymes are a particular concern and increasingly disseminated worldwide.1,2

Infections caused by MBL-producing Gram-negative bacteria are often resistant to multiple drugs, leaving few obvious treatment options.1

In 2020, WHO (World Health Organization) highlighted that lack of private investment and

innovation in the development of new antibiotics is undermining efforts to fight resistant

infections.3 Meanwhile, Gram-negative bacteria expressing MBLs continue to spread and evolve, with resistance to all β-lactam antibiotics.2

Without continued research and treatment breakthroughs, infections caused by Gram-negative bacteria expressing MBLs could soon become totally untreatable.1


Unlike many large research-based pharmaceutical companies, Pfizer is still active in R&D,

focused on the treatment and prevention of infections caused by difficult-to-treat resistant


We are committed to closing critical treatment gaps around the world, such as the treatment of Gram-negative bacterial and invasive fungal infections.4


Quid ex eo est consecutus? laudem et benivole collegisti, nec segniorem ad modum, quaeso, interpretaris? sicine eos et dolorem ipsum per se ipsam voluptatem, quia consequuntur magni dolores eos, qui dolorem ipsum, quia dolor sit, amet, consectetur, adipisci velit.

TitleExample Text How is Pfizer making an impact? Learn more

Innovation and investment will help to halt the progress of antibacterial resistance. Coming

together as a team of stewardship champions could stop the spread for good.

How to identify Gram-positive infections

TitleExample Text Pinpoint the positive Learn more
AMR, antimicrobial resistance; MBL, metallo-β-lactamase; R&D, research & development; WHO, World Health Organization.
ReferencesBoyd SE et al. Antimicrob Agents Chemother 2020;64(10):e00397-20.Mojica MF et al. Lancet Infect Dis 2022;22(1):e28–e34.World Health Organization. Lack of new antibiotics threatens global efforts to contain drug-resistant infections. 2020. Available at: Accessed August 2023.Pfizer. Our Commitment as a Global Anti-Infectives Leader. Available at: Accessed August 2023.
Bacterial Infections
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.

Copyright © 2024 Pfizer Limited. All rights reserved.